Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action

Gothenburg, April 27, 2022 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation immuno-oncological treatments based on enhanced CAR T-cells and oncolytic viruses, announced today it has concluded preclinical proof-of-concept studies for its oncolytic virus ELC-201. The study results confirm ELC-201’s proposed mode-of-action.ELC-201 is a next-generation oncolytic virus that has been genetically modified to enable treatment of most cancers. The drug candidate has been armed with Elicera’s proprietary platform technology, iTANK,

Sleep Cycle interim report January – March 2022: Greater efficiency in marketing and continued growth resulted in improved operating margin

Net sales increased by 19.2% to SEK 50.1 million, equivalent to an increase of 21.3% adjusted for currency effects. Sales continued to increase from the previous quarter, mainly as a result of product investments that had a positive effect on the conversion rate and thereby drove new users. Greater efficiency allowed for lower investments in marketing with a sustained effect, which had positive effects on the operating margin during the quarter. The total number of users at the close of the period was 920,000, equivalent to a growth of 12.2%.First quarter summary (January-March 2022) ·

Sustainability in every strategic decision – Kappahl publishes its 2021 sustainability report today

Kappahl is publishing its 2021 sustainability report today. It sets out a new climate change strategy, a new code of conduct and new collaborations that clearly demonstrate its serious commitment to sustainability.“During the year, we brought Sandra Roos, Vice President Sustainability, into Kappahl’s Group Management team. With Sandra present, we can now incorporate sustainability considerations into all strategic decisions at an early stage,” says Kappahl’s CEO Elisabeth Peregi. “Placing my role in the management team enables us to progress more quickly on our sustainability journey.

Interim report January-March 2022

Alelion delivers on record order intake of 2021, increasing net sales by 66 percentDuring the first quarter, net sales increased to MSEK 24.2 (14.6), a growth of 66 percent. Order intake reached MSEK 8.5 (22.7), which is mostly attributable to the strong conclusion of 2021 where customers placed orders for a long time ahead. We are seeing customers adopting a different pattern of placing orders, now preferring larger contracts with blanket orders rather than smaller-volume orders in incremental steps. Overall, Alelion received orders for MSEK 184 during 2021. This is on par with the peak

Mentice publishes the company’s interim report for the period January–March 2022

A strong start for the year with continued overall growth· Our strong finish of 2021 is now followed by a first quarter of 2022 with considerable growth for both order intake and net sales. We increased the order book to 91.4 (72.9) MSEK compared to the end of 2021 (87.1) MSEK. · The orderbook now consists of 72% Annual Recurring Revenue based components adding up to 66 MSEK out of the total of 91.4 MSEK. · Net sales for the first quarter of 53.1 (32.3) MSEK, corresponding to an increase of 64.2% compared to the same period last year and the order intake was 54.4 (39.9) MSEK an

Cereno Scientific nominates drug candidate CS585 in PCA Program for continued development in cardiovascular disease

Cereno Scientific (XSAT: CRNO B) today announced that drug candidate CS585 has been nominated for continued development in the preclinical Prostacyclin Analog (PCA) Program after completing initial preclinical studies. The drug candidate was nominated after demonstrating highest potential in cardiovascular disease among a set of similar molecules. CS585 will continue in its preclinical development program with the aim to provide a better treatment for patients with cardiovascular disease.“I am pleased to see a candidate nominated in our PCA Program as it signifies progress and proven

2020 Bulkers Ltd. (2020) - Results for the first quarter of 2022

Hamilton, Bermuda, April 27, 2022 2020 Bulkers Ltd. (“2020 Bulkers” or the “Company”), today announced its unaudited financial and operating results for the three months ended March 31, 2022. Key events during the first quarter of 2022 -          The Company reported net profit of US$5.9 million and EBITDA of US$11.0 million for the first quarter of 2022.   -          Achieved average time charter equivalent earnings of approximately US$24,000, per day, gross.   -          The Company declared total cash distributions of US$0.26 per share for the months of January,

AFRY enters partnership with leading industrial cyber security company OTORIO

The partnership empowers AFRYs already strong commitment to being a market leader in the industrial cyber security field.As the cyber risk environment evolves, companies will need to keep up with threats to sustaining continuous safe operations. The partnership with OTORIO enables AFRY to deliver managed end-to-end OT (operational technology) risk management as well as zero-trust solutions that combat threats before they appear. It enables highly competitive and proactive OT-security services that permit industrial businesses to stay ahead of threats without interruptions or downtime. AFRY,

Enhertu granted BTD for HER2-low breast cancer

27 April 2022 07:00 BST Enhertu granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer Based on DESTINY-Breast04 results where AstraZeneca and Daiichi Sankyo's Enhertu demonstrated a significant improvement in both progression-free survival and overall survival Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US

Alimak Group: Interim report January – March 2022

Focus on profitable growth · Continued profit improvement driven by revenue growth and improved gross margin · Continued strong order growth in Services · Organic revenue growth of 3% for the Group despite impacts from exiting of tower internals · Full speed to execute on phase three of the New Heights Programme, profitable growthFirst quarter 2022 · Order intake decreased by 2% to MSEK 1,053 (1,073) with an organic decrease of 9% · Service order intake increased 7% organically excluding Rental · Revenue increased by 11% to MSEK 936 (846) with an organic increase of

Interim report for first quarter 2022

A broader and stronger licensing business strengthens our position in infection preventionFirst quarter (January-March 2022) · Revenues amounted to SEK 55.2 (41.8) million, an increase of 32%, mainly through higher licensing revenues. Adjusted for currency the increase was 23%. · EBITDA amounted to SEK -4.0 (1.9) million with an EBITDA-margin of -7% (5%), a result of initiated investments in accordance with the focused growth strategy. · Operating profit amounted to SEK -16.6 (-9.7) million. · Net loss for the period amounted to SEK -16.5 (-10.5) million. Earnings per share

Alligator Bioscience AB: Interim report January–March 2022

A Quarter of Advancements for Alligator’s Key Assets “Q1 2022 was marked by many important advancements. We made progress with our key assets, mitazalimab and ATOR-1017, and ATOR-4066 and welcomed a new Chief Medical Officer to strengthen our medical leadership.” Søren Bregenholt, CEO Alligator Bioscience AB SIGNIFICANT EVENTS JANUARY-MARCH Pipeline: · In March, the Company successfully completed the Phase Ib part of the clinical study OPTIMIZE-1, and Phase II is now enrolling patients at the recommended dose of 900 µg/kg. · In January, Alligator initiated a sponsored

Quarterly Report Q1 2022

A strong start to the yearFirst quarter · Net sales increased by 22% to SEK 26,591 M (21,805), with organic growth of 14% (4) and acquired net growth of 0% (4) · Very strong organic sales growth in Americas, Entrance Systems and Global Technologies and strong growth in EMEIA, while organic sales declined in Asia Pacific · Three acquisitions with combined annual sales of about SEK 250 M were signed in the quarter · Operating income (EBIT) was SEK 4,001 M (3,187), corresponding to an operating margin of 15.0% (14.6) · Net income[ ]amounted to SEK 2,859 M (2,253) · Earnings

Modeling published in Neurology and Therapy suggests that lecanemab could delay progression to Alzheimer's dementia by several years

Stockholm, April 27, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that an article about long-term health outcomes of the investigational anti-amyloid-beta (Aβ) protofibril antibody lecanemab (BAN2401) in people living with early Alzheimer’s disease (AD), using disease modeling, was published in the peer-reviewed journal Neurology and Therapy. In this simulation, lecanemab treatment is estimated to slow the rate of disease progression, maintaining treated patients for a longer duration in earlier stages of the disease.The article focuses on the long-

Peafowl Plasmonics raises 40 MSEK to bring transparent solar power to the market

Peafowl Plasmonics takes the next step on their commercialization journey. With this seed round of funding, co-led by Industrifonden and Navigare Ventures, and backed by current owners, the company is disrupting energy supply with transparent solar power to replace batteries and cables, making our world greener, smarter, and more sustainable.The necessity to reduce energy consumption and the ever-increasing demand for renewable energy sources are driving the development of new technology. Peafowl’s direct plasmonic light harvesting cell converts light into electricity, using plasmonic

Interim Report January – March 2022

· Net sales totaled SEK 32,574 (15,723) thousand, with a growth rate of 107%. About SEK 10 million relates to the license agreement in 2021 with Selecta Biosciences. Growth is 91%, adjusted for currency effects. · Gross profit rose by 96% to SEK 29,419 (15,017) thousand. · Operating profit before depreciation and amortization (EBITDA) totaled SEK 11,717 (1,958) thousand. · Operating profit jumped SEK 9,554 thousand and totaled SEK 10,105 (551) thousand. · Comprehensive income for the period improved by SEK 11,476 thousand and totaled SEK 13,083 (1,607) thousand. · Comprehensive

Crusher economy for every business - Metso Outotec introduces renewed crusher wear offering

Metso Outotec Corporation’s press release on April 27, 2022, at 09:00 a.m. EESTMetso Outotec is introducing its renewed crusher wears solution offering catering the industry’s widest variety of wear parts and services enabling customers’ sustainable, predictable, and profitable crushing. The portfolio is categorized to three different product ranges – Metso Outotec O-Series, Expert Series and Max Series. The renewed crusher wears and services offering, from seasonal crushing to high-volume, and high-value operations has been developed in response to customers’ demand for continuous

Invitation to Concentrics' presentation of the Interim Report for the first quarter 2022

Concentric's Interim Report January-March 2022, will be published on 4 May 2022, at 08.00 CET. At 10.00 CET media, investors and analysts are invited to Stockholm City Conference Center Drottninggatan 71b, Stockholm, for a presentation of the report. There will also be an opportunity to participate via telephone conference/audio cast. President & CEO Martin Kunz and CFO Marcus Whitehouse will host the presentation, which will be held in English and is followed by Q&A sessions. We look forward to your participation. See below detailed information: WEBCAST LINK 

Viaplay to show Scottish, Welsh and Northern Irish national team football in UK

· Viaplay to stream Scotland’s, Wales’ and Northern Ireland’s European Qualifiers to the FIFA World Cup 2026 and UEFA EURO 2028, UEFA Nations League 2024/25 and 2026/27 and international friendlies exclusively in UK · Over 800 National Team Football matches from across Europe, including top-ranked teams such as Belgium, Denmark, France, Germany, Italy, the Netherlands, Portugal and Spain shown exclusively on Viaplay · Viaplay to launch in UK in second half of 2022 Viaplay and UEFA have entered a four-year partnership in the UK for Viaplay to show at least 40 exclusive live matches

The shares in DNB Bank ASA will be quoted ex-dividend today

The shares in DNB Bank ASA will be quoted ex-dividend on 27 April 2022. A dividend of NOK 9.75 per share will be distributed on 5 May 2022 to registered shareholders as at 26 April 2022. For further information, please contact: Rune Helland, head of Investor Relations, tel: +47 977 13 250 This information is subject to the disclosure requirements according to Section 5-12 of the Norwegian Securities Trading Act.

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2021

GOTHENBURG, Sweden, April 27, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced that the company's annual report and corporate governance report for the financial year 2021 are now available on the company's website, www.isofolmedical.com .For further information, please contact Isofol Medical AB (publ)Jarl Ulf Jungnelius, M.D., Chief Executive Officer  E-mail: jungnelius@isofolmedical.com  Phone: +46 (0) 709 16 89 55   Gustaf Albèrt, CFO and deputy CEOE-mail: gustaf.albert@isofolmedical.com

Changes in Handelsbanken’s executive management

Monika Bergström has been appointed Chief Compliance Officer at Handelsbanken and will be co-opted to Handelsbanken’s Group executive management. Monika Bergström is currently acting Head of Group Compliance and was previously the deputy head. “I am delighted to welcome Monika Bergström as Chief Compliance Officer at Handelsbanken. An obvious appointment, given Monika’s long-time experience in the Bank and extensive knowledge of compliance”, says Carina Åkerström, President and Group Chief Executive Officer at Handelsbanken. ”I am very pleased to be entrusted with the role of Chief

Finnair Group Interim Report 1 January – 31 March 2022

Finnair Plc                  Interim Report                 27 April 2022 at 9.00 a.m. EEST Recovery from the pandemic progresses at pace whilst we are adapting to the reality of the closed Russian airspace   January – March 2022 · Earnings per share were -0.15 euros (-0.11)*. · Revenue increased by 252.1% to 399.8 million euros (113.6). · Comparable operating result was -132.9 million euros (-143.2). Operating result was -164.9 million euros (-149.1). · Cash funds were 1,136.5 million euros (31 Dec 2021: 1 265.7) and the equity ratio was 7.2 per cent (31 Dec 2021: 11.8).

Hybrid loan granted by the State of Finland to Finnair converted to capital loan

Finnair Plc                  Stock Exchange Release                 27 April 2022 at 9.00 a.m. EEST  Finnair and the State of Finland signed an agreement on a hybrid loan of maximum 400 million euros to support Finnair due to the COVID-19 pandemic in March 2021. The arrangement has the approval of the EU Commission’s competition authority in line with the European Union’s state aid rules and, therefore, the entire amount of 400 million euros is available for Finnair to use. In its meeting on 19 April 2022, the Ministerial Committee on Economic Policy supported the conversion of the

There are no items matching the current filter
There are no more items matching the current filter
Back to top